Recent developments highlight CERo Therapeutics' clinical progress with CER-1236, regulatory designations, financing activities, and analyst coverage.

• D. Boral Capital maintained a Buy recommendation on CERo Therapeutics Holdings in October 2025 [N1][N2][N3].
• CER-1236 received FDA Fast Track Designation in September 2025 [N4].
• No dose-limiting toxicities were reported in the first patient cohort of the Phase 1 trial for CER-1236, supporting safety [N5].
• CERo announced completion of initial patient evaluation in the Phase 1 clinical trial of CER-1236 for acute myeloid leukemia in June 2025 [N6].
• CER-1236 received FDA Orphan Drug Designation for acute myeloid leukemia treatment in June 2025 [N7][N8].

CERo Therapeutics' lead candidate CER-1236 has demonstrated a favorable safety profile in early Phase 1 trials with no dose-limiting toxicities and observed cell expansion, suggesting potential for therapeutic activity. The FDA's Orphan Drug and Fast Track designations for CER-1236 in AML indicate regulatory recognition of unmet medical need and may facilitate development. The platform's novel mechanism targeting TIM-4 ligand could enable treatment across multiple cancer types, including solid tumors where current CAR-T therapies have limited success. The company's manufacturing approach aligns with established CAR-T processes, potentially easing regulatory and commercial pathways. Positive analyst coverage and recent financing support ongoing development efforts.

CERo Therapeutics faces significant risks as a clinical-stage biopharmaceutical company with no approved products and a history of substantial net losses. Its limited liquidity and low current ratio raise concerns about sustaining operations without additional financing. The delisting from Nasdaq and trading on OTCQB may reduce market liquidity and investor access. Clinical development carries inherent risks including potential failure to demonstrate safety or efficacy, regulatory delays, and manufacturing challenges. The novel CER-T platform, while promising, remains unproven in humans beyond early trials. Dependence on third-party suppliers and manufacturing partners adds operational risk. Failure to secure sufficient capital or achieve regulatory approvals could materially impair the company's prospects.

CERo Therapeutics' moat lies in its proprietary CER-T cell platform that integrates both innate and adaptive immune mechanisms, potentially overcoming limitations of existing CAR-T therapies, especially in solid tumors where CAR-T has limited efficacy. The targeting of TIM-4 ligand, broadly expressed on tumor cells but minimally on healthy cells, may reduce off-target toxicities. The company benefits from leveraging established CAR-T manufacturing and regulatory pathways, which may shorten development timelines. Its portfolio of 18 patents and applications supports its immunotherapy technology. However, as a clinical-stage company without approved products, its moat is contingent on successful clinical development and regulatory approvals.

• Clinical Development Risk: CERo's lead product candidate CER-1236 is in early-stage clinical trials, and there is no guarantee of safety or efficacy outcomes necessary for regulatory approval.
• Financial and Liquidity Risk: The company reported a net loss of $19.9 million in 2025 with limited cash and liquidity ratios below 1, raising substantial doubt about its ability to continue as a going concern without additional financing.
• Regulatory and Market Access Risk: Delisting from Nasdaq and trading on OTCQB may reduce liquidity and investor interest, potentially impacting the company's ability to raise capital and commercialize products.
• Manufacturing and Supply Chain Risk: CERo relies on third-party suppliers and manufacturing processes similar to CAR-T therapies, which may face capacity constraints, quality issues, or disruptions.
• Competitive and Technological Risk: The immunotherapy field is highly competitive with rapid technological advances; CERo's novel CER-T platform must demonstrate clear advantages over existing CAR-T and other therapies.

• CERo Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on next-generation engineered T cell therapeutics for cancer treatment [S1].
• The company’s proprietary platform creates Chimeric Engulfment Receptor T (CER-T) cells that integrate innate and adaptive immune system functions to target tumors via cytotoxic and phagocytic mechanisms [S1].
• Lead product candidate is CER-1236, an autologous T-cell therapy targeting TIM-4 ligand, a tumor antigen broadly expressed on hematological malignancies and solid tumors [S1].
• CER-1236 is designed to overcome limitations of current CAR-T therapies, potentially active in both hematological and solid tumors [S1].
• The company initiated a Phase 1 clinical trial of CER-1236 in acute myeloid leukemia (AML) patients in May 2025, with five patients dosed as of March 2026 [S1].
• The Phase 1 trial includes dose escalation and expansion phases, with primary endpoints including safety, dose-limiting toxicities, and response rates [S1].
• No dose-limiting toxicities were reported in the first four patients, and the therapy showed cell expansion post-infusion [S1].
• The trial was expanded to include myelodysplastic syndrome (MDS) and myelofibrosis (MF) based on early safety and efficacy signals [S1].
• CER-1236 received FDA Orphan Drug Designation for AML treatment in July 2025 and Fast Track Designation in September 2025 [S1].
• The company plans to initiate Phase 1 studies for CER-1236 in non-small cell lung cancer (NSCLC) and ovarian cancer in 2026 [S1].
• Manufacturing of CER-1236 uses processes similar to approved CAR-T therapies, leveraging established regulatory pathways [S1].
• CERo Therapeutics had eight full-time employees as of December 31, 2025, including six in research and development [S1].
• Financial snapshot as of December 31, 2025: cash and equivalents $1.9 million (as of 2025-09-30), current assets $2.73 million, current liabilities $9.09 million, net loss $19.9 million for FY 2025, basic and diluted EPS of -9.1 USD/shares for Q3 2025 [S1].
• Liquidity ratios as of 2025-12-31: current ratio 0.3, cash ratio 0.21, indicating limited short-term liquidity [S1].
• The company has incurred significant losses since inception and expects to continue incurring losses as it advances clinical development [S1].
• CERo Therapeutics was delisted from Nasdaq in October 2025 and now trades on OTCQB, which may reduce liquidity and trading volume [S1].
• The company has issued convertible promissory notes in early 2026 to Keystone Capital Partners, providing additional financing [S1].
• CERo holds 18 patents and applications expanding its immunotherapy portfolio [N6].
• The company’s clinical trial data and regulatory designations have been covered in multiple news articles, including positive analyst recommendations [N1][N2][N3][N4][N5][N6][N7][N8].